Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation
ABSTRACT Chimeric antigen receptor T‐cell (CAR‐T) therapy is a transformative tumor immunotherapy that redirects autologous T cells to eliminate malignant cells. However, its broader clinical translation is constrained by complex and costly ex vivo manufacturing, variable product quality, and limited control over in vi...